Clinical trials: Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML
The aim of this study is to reveal the influence of gene mutations on the treatment response of the regimen of HHT combined with Venetoclax plus AZA versus venetoclax plus HMA in the salvage therapy of RR-AML.
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Gene Abnormality, Cytogenetic Abnormality
- Trial name
- NCT05456048
- Testing
- VAH regimen, VEN+HMA regimen
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Refractory Acute Myeloid Leukemia, Relapsed Acute Erythroid Leukemia
Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML
Up Until now, there is not well acepted treatment for relapsed/refractory (rr) acute myeloid luekemia (AML), which has low complete response and poor survival.
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Erythroid Leukemia, Salvage Treatment, HVA Regimen
- Trial name
- NCT04424147
- Testing
- HVA Regimens as Salvage Treatment
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia
This is a single-arm, single-center clinical study to assess the efficacy and safety of Mitoxantrone Hydrochloride Liposome combined with cladribine and sotoraclib in patients with relapsed/refractory acute myeloid leukemia…
- Trial name
- NCT07874737
- Testing
- Mitoxantrone Hydrochloride Liposome+cladribine+sotoraclib
- Volunteers
- 20 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory, Refractory/Relapse Acute Myeloid Leukemia
- Trial name
- KNAN2001 (NCT04716452)
- Testing
- Ceramide NanoLiposome (Ceraxa)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Keystone Nano, Inc
Acute Myeloid Leukemia
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid…
- Trial name
- NCT06328179
- Testing
- Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Huai'an First People's Hospital
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
- Trial name
- NCT06125652
- Testing
- anti Tim-3/CD123 CAR-T cell therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuzhou Medical University
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
To evaluate the safety and efficacy of anti-Siglec-6 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
- Trial name
- NCT05488132
- Testing
- anti-siglec-6 CAR-T cell therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuzhou Medical University
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved selectivity, potentially reducing toxicity.
- Trial name
- NCT07137637
- Testing
- HPB-092 tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hangzhou Polymed Biopharmaceuticals, Inc.